Clear-positive cut off determination of flow cytometric MOG-antibody assay in Korea: Alignment with international MOGAD diagnostic standards

IF 3.1 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2026-01-15 Epub Date: 2025-11-10 DOI:10.1016/j.jneuroim.2025.578806

Young Nam Kwon , Woohee Ju , Jae hyun Jeon , Chorong Hahm , Jung-Joon Sung , Sung-Min Kim

{"title":"Clear-positive cut off determination of flow cytometric MOG-antibody assay in Korea: Alignment with international MOGAD diagnostic standards","authors":"Young Nam Kwon , Woohee Ju , Jae hyun Jeon , Chorong Hahm , Jung-Joon Sung , Sung-Min Kim","doi":"10.1016/j.jneuroim.2025.578806","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>MOG-Ab assay is a sensitive and specific biomarker that is indispensable in diagnosis of MOG antibody-associated disease (MOGAD). However, its accuracy can largely depend on a proper selection of patients also on cut-off value setting. We updated the cut-off value of flow cytometric MOG antibody assay in Korea, into low- and clear-positive, in alignment with 2023 International MOGAD Panel proposal.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 695 patients who underwent live cell-based flow cytometric MOG-Ab testing at Seoul National University Hospital from August 2023 to January 2024. Cut-off values for mean fluorescence intensity ratio (MFIr) were determined using disease controls, and diagnostic accuracy was assessed at three thresholds: Low Positive (>2.61), Clear-Positive (>5.66), and High Clear-Positive (>10.0).</div></div><div><h3>Results</h3><div>Among 671 non-MS/NMOSD patients, 159 had core clinical demyelinating events, and 66 met 2023 international panel criteria for MOGAD. The diagnostic accuracies for low-positive, clear-positive, and high clear-positive results were as follows: sensitivity of 100 %, 59.1 %, and 33.3 %, respectively; specificity of 95.7 %, 95.9 %, and 100 %; positive predictive value (PPV) of 71.0 %, 90.7 %, and 100 %; and negative predictive value of 100 %, 95.9 %, and 93.5 %. In 159 patients with core clinical demyelinating events excluding MS and NMOSD, clear-positive threshold demonstrated a PPV of 100 %.</div></div><div><h3>Conclusion</h3><div>This study updates the cut-off values of flow cytometric MOG-Ab assay and its diagnostic accuracies in Korea in accordance with the 2023 International Panel recommendation. Our findings can contribute to improving the diagnostic accuracy of MOGAD in Korea and to strengthening the scientific validity of MOGAD research data from Korean cohort.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"410 ","pages":"Article 578806"},"PeriodicalIF":3.1000,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825002875","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

MOG-Ab assay is a sensitive and specific biomarker that is indispensable in diagnosis of MOG antibody-associated disease (MOGAD). However, its accuracy can largely depend on a proper selection of patients also on cut-off value setting. We updated the cut-off value of flow cytometric MOG antibody assay in Korea, into low- and clear-positive, in alignment with 2023 International MOGAD Panel proposal.

Methods

We retrospectively analyzed 695 patients who underwent live cell-based flow cytometric MOG-Ab testing at Seoul National University Hospital from August 2023 to January 2024. Cut-off values for mean fluorescence intensity ratio (MFIr) were determined using disease controls, and diagnostic accuracy was assessed at three thresholds: Low Positive (>2.61), Clear-Positive (>5.66), and High Clear-Positive (>10.0).

Results

Among 671 non-MS/NMOSD patients, 159 had core clinical demyelinating events, and 66 met 2023 international panel criteria for MOGAD. The diagnostic accuracies for low-positive, clear-positive, and high clear-positive results were as follows: sensitivity of 100 %, 59.1 %, and 33.3 %, respectively; specificity of 95.7 %, 95.9 %, and 100 %; positive predictive value (PPV) of 71.0 %, 90.7 %, and 100 %; and negative predictive value of 100 %, 95.9 %, and 93.5 %. In 159 patients with core clinical demyelinating events excluding MS and NMOSD, clear-positive threshold demonstrated a PPV of 100 %.

Conclusion

This study updates the cut-off values of flow cytometric MOG-Ab assay and its diagnostic accuracies in Korea in accordance with the 2023 International Panel recommendation. Our findings can contribute to improving the diagnostic accuracy of MOGAD in Korea and to strengthening the scientific validity of MOGAD research data from Korean cohort.

Abstract Image

查看原文本刊更多论文

韩国流式细胞术mog抗体测定的明确阳性切断测定：与国际MOGAD诊断标准一致。

背景：MOG- ab检测是诊断MOG抗体相关疾病（MOGAD）不可缺少的一种敏感、特异的生物标志物。然而，其准确性在很大程度上取决于患者的正确选择，也取决于临界值的设置。根据2023年国际MOGAD小组的建议，我们将韩国流式细胞术MOG抗体检测的临界值更新为低阳性和明确阳性。方法：我们回顾性分析了2023年8月至2024年1月在首尔国立大学医院接受活细胞流式细胞术MOG-Ab检测的695例患者。使用疾病对照确定平均荧光强度比（MFIr）的临界值，并在三个阈值下评估诊断准确性：低阳性（>2.61）、清晰阳性（>5.66）和高清晰阳性（>10.0）。结果：在671例非ms /NMOSD患者中，159例有核心临床脱髓鞘事件，66例符合2023年MOGAD国际小组标准。低阳性、清晰阳性和高清晰阳性的诊断准确率分别为100%、59.1%和33.3%；特异性分别为95.7%、95.9%和100%；阳性预测值分别为71.0%、90.7%和100%；阴性预测值分别为100%、95.9%、93.5%。在159例核心临床脱髓鞘事件（不包括MS和NMOSD）患者中，明确阳性阈值显示PPV为100%。结论：根据2023年国际专家组的建议，本研究更新了韩国流式细胞术MOG-Ab测定的临界值及其诊断准确性。我们的研究结果有助于提高韩国MOGAD的诊断准确性，并加强韩国队列MOGAD研究数据的科学有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.